|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.79/-0.84
|
企业价值
236.75M
|
资产负债 |
每股账面净值
1.82
|
现金流量 |
现金流量率
--
|
损益表 |
收益
130.00K
|
每股收益
0.17
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/12/24 12:44 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others. |